Summary & Overview
HCPCS Level II C9063: Injection, eptinezumab-jjmr, 1 mg
HCPCS Level II code C9063 designates a unit of the injectable biologic eptinezumab-jjmr, dosed per milligram, used in the prevention of migraine. As a drug-specific HCPCS Level II code, C9063 is relevant to billing for infused or injected specialty therapies in outpatient infusion centers, physician offices, and other ambulatory settings. Nationally, clear HCPCS coding for high-cost biologics affects coverage determinations, reimbursement workflows, and prior authorization processes across payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical role and service context, summaries of payer coverage considerations, and benchmarks where available. The publication outlines common billing practices for unit-based HCPCS drug codes, points of payer variability to expect with specialty biologics, and policy updates that typically affect HCPCS drug coding and reimbursement.
This summary equips revenue cycle professionals, clinicians, and policy stakeholders with the essential facts about HCPCS Level II code C9063, the service types and sites where the drug is administered, and the national payer landscape relevant to billing and coverage for eptinezumab-jjmr injections.
Billing Code Overview
HCPCS Level II code C9063 represents Injection, eptinezumab-jjmr, 1 mg, a parenteral biologic medication administered by intravenous or subcutaneous injection for migraine prevention. The service type is drug administration/injectable biologic, and the typical site of service is an infusion center, outpatient clinic, or physician office where specialty biologic injections are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 38-year-old patient with a history of chronic migraine who has not responded adequately to two or more preventive therapies presents to an outpatient infusion center for administration of a preventive monoclonal antibody therapy. The medication administered is eptinezumab-jjmr dosed and billed per milligram as C9063 (Injection, eptinezumab-jjmr, 1 mg). The typical workflow includes pre-visit verification of insurance benefits and prior authorization, baseline review of headache frequency and prior treatments, medication preparation by pharmacy, intravenous infusion or IV push per product labeling in an ambulatory infusion suite or physician office, monitoring for infusion-related reactions during and for a short observation period after administration, documentation of lot number and amount administered, and charge capture using the per-milligram HCPCS code C9063 multiplied by the number of milligrams administered. Typical site of service is an outpatient infusion center, ambulatory infusion suite, or physician office with IV administration capability. Common clinical considerations include screening for hypersensitivity to monoclonal antibodies, assessment of pregnancy status if applicable, and coordination of dosing intervals for preventive therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |